Uhlmann Group Spins Off visiotec GmbH - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Uhlmann Group Spins Off visiotec GmbH


An independent subsidiary of Uhlmann Germany, visiotec GmbH, was created on April 1, 2013 to focus on inspection, monitoring, and control systems for automated pharmaceutical manufacturing processes, the company announced in a press release.

The spin-off addresses the pharmaceutical industry’s demand for a more holistic approach beyond the traditional borders of manufacturing and packaging, said the company. Visiotec will provide solutions for product quality and safety using inline monitoring, based on its expertise in process analytical technologies, such as high-speed, near-infrared analysis and advanced mass-verification technology.

Visiotec GmbH will operate globally from offices in Germany, Switzerland, and the United States. The printing, inspection, and track-and-trace products formerly offered by Uhlmann VisioTec GmbH for packaging applications will be handled by the Uhlmann Group’s dedicated Uhlmann Customer Services division.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here